IMMUNOGENICITY ASSAY FACILITY

IMMUNOGENICITY FACILITY

(An Initiative of ILS and BIRAC)

ILS Bhubaneswar has established a state-of-the-art clinical immunogenicity assay platform to facilitate SARS-CoV-2 related clinical investigations and vaccine development with the help of DBT-BIRAC. The facility will provide services for testing and validation of vaccine efficacy and safety against SARS-CoV-2 in human subjects on a fee-for-service basis.

We have developed standard operating procedures and advanced instrumentation facility for sensitive, precise and reproducible test results.


Current status of No. of assays and individuals
@ Immunogenicity Assay Platform
imgen


No. of tests with various variants of SARS-CoV-2
imgen


COVID-RBD specific antibody profiling in infected patients,
direct contacts and controls
imgen


imgen


Longitudinal profiling of COVID-RBD IgG antibodies in COVID
vaccinated subjects
imgen


Pseudo-virus neutralization activity using serum of COVID
infected patients, their direct contacts and controls
imgen


Cytokine profiling of COVID infected patients infected patients,
their direct contacts and controls
imgen


Outline depicting T-cell profiling from COVID-19 vaccinated
subjects
imgen